Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the safety and clinical effect of daily oral treatment with
laquinimod capsules in active lupus nephritis patients. This study will assess Laquinimod
doses of 0.5mg /day and 1 mg/day in combination with standard of care treatment
(mycophenolate mofetil and corticosteroids). Laquinimod is a novel immunomodulating drug
which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for
Multiple Sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries